Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2411
Abstract: Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously… read more here.
Keywords: previously treated; patients previously; ono 4538; ono ... See more keywords
Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5652
Abstract: Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized… read more here.
Keywords: dose nab; previously treated; nab paclitaxel; phase trial ... See more keywords
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33990
Abstract: BACKGROUND Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor β (PDGFR-β), and fibroblast growth factor receptors (FGFRs). This study explored the… read more here.
Keywords: thymic carcinoma; study; rate; previously treated ... See more keywords
Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34493
Abstract: At an interim analysis (median follow‐up, 6.2 months; n = 187), the phase 3 COSMIC‐311 trial met the primary end point of progression‐free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs.… read more here.
Keywords: previously treated; cosmic 311; treated radioiodine; 311 trial ... See more keywords
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34532
Abstract: KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 (PD-L1)-positive, advanced non-small cell lung cancer (NSCLC), with most patients enrolled in mainland China. Eligible… read more here.
Keywords: pembrolizumab docetaxel; docetaxel previously; keynote 033; previously treated ... See more keywords
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3678-5
Abstract: PurposeOptimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the… read more here.
Keywords: chemotherapy; gastric cancer; ramucirumab; treated fluoropyrimidine ... See more keywords
Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Research in Cardiology"
DOI: 10.1007/s00392-018-1379-z
Abstract: PurposeWhile statins are used as first-line treatments for high-risk patients with hypercholesterolemia, statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol (LDL-C) levels. Second-line treatment options include up-titration of statin dose, switching to… read more here.
Keywords: risk; rosuvastatin; high risk; treated statin ... See more keywords
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01077-7
Abstract: Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and… read more here.
Keywords: nivolumab monotherapy; response; dissociated response; previously treated ... See more keywords
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-019-02145-4
Abstract: Purpose To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. Materials and methods We conducted a retrospective, post-authorized,… read more here.
Keywords: patients previously; previously treated; her2 positive; breast cancer ... See more keywords
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0855-5
Abstract: Fulvestrant (Faslodex®), a selective estrogen receptor (ER) degrader, is now indicated for the treatment of ER+ or hormone-receptor positive (HR+)/HER2− advanced breast cancer in postmenopausal women previously untreated with endocrine therapy. In the phase 3… read more here.
Keywords: endocrine therapy; advanced breast; breast cancer; previously treated ... See more keywords
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2019.01.006
Abstract: Introduction: Data on immuno‐oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab in a predominantly Chinese patient population with previously treated NSCLC. Methods:… read more here.
Keywords: versus docetaxel; population previously; previously treated; predominantly chinese ... See more keywords